Karyopharm Therapeutics Inc. (KPTI)

1.0600 0.0000 (0.00%) At close: 04:00PM EDT

Karyopharm Therapeutics Inc.

85 Wells Avenue
Suite 210
Newton, MA 02459-3298
United States
617 658 0600
https://www.karyopharm.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 325

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Richard A. Paulson M.B.A.	President, CEO & Director	1.43M	N/A	1967
Ms. Sohanya Cheng M.B.A.	Executive VP & Chief Commercial Officer	742.95k	N/A	1983
Mr. Stuart Poulton	Executive VP & Chief Development Officer	682.48k	N/A	N/A
Dr. Reshma Rangwala M.D., Ph.D.	Executive VP, Chief Medical Officer & Head of Research	777.32k	N/A	1978
Dr. Mansoor Raza Mirza M.D.	Clinical Consultant, Member of Scientific Advisory Board & Independent Director	150k	N/A	1961
Dr. Sharon Shacham M.B.A., Ph.D.	Co-Founder & Chairman of Scientific Advisory Board	1.4M	N/A	1970
Mr. Cameron Peters	Vice President of Finance, Assistant Treasurer & Principal Accounting Officer	N/A	N/A	1960
Ms. Elhan Webb C.F.A.	Senior Vice President of Investor Relations	N/A	N/A	N/A
Mr. Michael J. Mano J.D.	Senior VP, General Counsel & Secretary	625.08k	N/A	1977
Mr. James Accumanno J.D.	Chief Compliance Officer	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.

Corporate governance

Karyopharm Therapeutics Inc.’s ISS governance QualityScore as of 1 April 2024 is 8. The pillar scores are Audit: 8; Board: 8; Shareholder rights: 8; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.